Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S
Background and Aims: Type IV collagen 7S (COL4-7S) is a simple, noninvasive biomarker for liver fibrosis. However, whether COL4-7S can detect advanced fibrosis (AF) and predict the prognosis of metabolic dysfunction–associated steatotic liver disease (MASLD) is unclear. We examined the clinical effi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Gastro Hep Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S277257232500055X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850153768041054208 |
|---|---|
| author | Hiroshi Ishiba Yoshio Sumida Yoshihiro Kamada Hideki Fujii Michihiro Iwaki Hideki Hayashi Hidenori Toyoda Satoshi Oeda Hideyuki Hyogo Miwa Kawanaka Asahiro Morishita Kensuke Munekage Kazuhito Kawata Tsubasa Tsutsumi Koji Sawada Tatsuji Maeshiro Hiroshi Tobita Yuichi Yoshida Masafumi Naito Asuka Araki Shingo Arakaki Takumi Kawaguchi Hidenao Noritake Masafumi Ono Tsutomu Masaki Satoshi Yasuda Eiichi Tomita Masato Yoneda Akihiro Tokushige Hirokazu Takahashi Shinichiro Ueda Shinichi Aishima Atsushi Nakajima Takeshi Okanoue |
| author_facet | Hiroshi Ishiba Yoshio Sumida Yoshihiro Kamada Hideki Fujii Michihiro Iwaki Hideki Hayashi Hidenori Toyoda Satoshi Oeda Hideyuki Hyogo Miwa Kawanaka Asahiro Morishita Kensuke Munekage Kazuhito Kawata Tsubasa Tsutsumi Koji Sawada Tatsuji Maeshiro Hiroshi Tobita Yuichi Yoshida Masafumi Naito Asuka Araki Shingo Arakaki Takumi Kawaguchi Hidenao Noritake Masafumi Ono Tsutomu Masaki Satoshi Yasuda Eiichi Tomita Masato Yoneda Akihiro Tokushige Hirokazu Takahashi Shinichiro Ueda Shinichi Aishima Atsushi Nakajima Takeshi Okanoue |
| author_sort | Hiroshi Ishiba |
| collection | DOAJ |
| description | Background and Aims: Type IV collagen 7S (COL4-7S) is a simple, noninvasive biomarker for liver fibrosis. However, whether COL4-7S can detect advanced fibrosis (AF) and predict the prognosis of metabolic dysfunction–associated steatotic liver disease (MASLD) is unclear. We examined the clinical efficacy of COL4-7S in diagnosing AF and determining MASLD prognosis. Methods: Overall, 881 Japanese patients with biopsy-proven nonalcoholic fatty liver disease between 1994 and 2020 were enrolled. Serum COL4-7S levels were measured by radioimmunoassay, and 2 cutoff points were set as 5.1 ng/mL and 7.2 ng/mL. The patients were assigned to 3 groups based on the COL4-7S level. Cox regression analysis was used to estimate the predictive performance of COL4-7S for liver-related events (LREs). Results: Overall, 866 MASLD patients were enrolled. The median follow-up period was 4.3 years. Thirty-one patients developed LREs. The area under the curve for COL4-7S in patients with AF was 0.847. The adjusted hazard ratios for LREs in 4.8 ≤ COL4-7S < 6.8 and COL4-7S ≥6.8 patients were 6.0 (P = .009) and 27.9 (P < .001) compared with COL4-7S <4.8, and the adjusted hazard ratio of AF on liver biopsy was 1.6 (P = .286). The incidence rate of LREs was low when the Fibrosis-4 Index (FIB-4) <1.30. When the FIB-4 >1.30, effective stratification of the LRE risk group was possible by stratification of COL4-7S. A combination of FIB-4 and COL4-7S stratified risk groups for future LRE development more effectively than when used singly. Conclusion: COL4-7S accurately diagnosed AF and predicted LREs. COL4-7S and a combination of FIB-4 and COL4-7S might help physicians estimate the prognosis of future LRE risk. |
| format | Article |
| id | doaj-art-79b9e202bc9e415cb5bdf9bda1583e85 |
| institution | OA Journals |
| issn | 2772-5723 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gastro Hep Advances |
| spelling | doaj-art-79b9e202bc9e415cb5bdf9bda1583e852025-08-20T02:25:37ZengElsevierGastro Hep Advances2772-57232025-01-014710066810.1016/j.gastha.2025.100668Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7SHiroshi Ishiba0Yoshio Sumida1Yoshihiro Kamada2Hideki Fujii3Michihiro Iwaki4Hideki Hayashi5Hidenori Toyoda6Satoshi Oeda7Hideyuki Hyogo8Miwa Kawanaka9Asahiro Morishita10Kensuke Munekage11Kazuhito Kawata12Tsubasa Tsutsumi13Koji Sawada14Tatsuji Maeshiro15Hiroshi Tobita16Yuichi Yoshida17Masafumi Naito18Asuka Araki19Shingo Arakaki20Takumi Kawaguchi21Hidenao Noritake22Masafumi Ono23Tsutomu Masaki24Satoshi Yasuda25Eiichi Tomita26Masato Yoneda27Akihiro Tokushige28Hirokazu Takahashi29Shinichiro Ueda30Shinichi Aishima31Atsushi Nakajima32Takeshi Okanoue33Department of Gastroenterology, Osaka General Hospital of West Japan Railway Company, Osaka, JapanGraduate School of Healthcare Management, International University of Healthcare and Welfare, Tokyo, Japan; Correspondence: Address correspondence to: Yoshio Sumida, MD, PhD, MBA, Graduate School of Healthcare Management, International University of Healthcare and Welfare, 4-1-26 Akasaka, Minato-ku, Tokyo 107-8402, Japan.Department of Advanced Metabolic Hepatology, Osaka University, Graduate School of Medicine, Suita, Osaka, JapanDepartments of Premier Preventive Medicine and Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Abeno, Osaka, JapanDivision of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, JapanDepartment of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, JapanDepartment of Gastroenterology, Ogaki Municipal Hospital, Ogaki, JapanDepartment of Laboratory Medicine, Liver Center, Saga University Hospital, Saga University Hospital, Saga, Japan; Department of Internal Medicine, Saga Medical School, Saga University, Saga, JapanHyogo Life Care Clinic, Minami, Hiroshima, JapanDepartment of General Internal Medicine, Kawasaki Medical Center, Kawasaki Medical School, Okayama, JapanDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, JapanDepartment of Gastroenterology and Hepatology, Kochi Medical School, Kochi, JapanHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, JapanDivision of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, JapanFirst Department of Internal Medicine, University of the Ryukyus Hospital, Nakagami, Okinawa, JapanDepartment of Hepatology, Shimane University Hospital, Izumo, Shimane, JapanDepartment of Gastroenterology and Hepatology, Suita Municipal Hospital, Suita, Osaka, JapanDepartment of Gastroenterology and Hepatology, Suita Municipal Hospital, Suita, Osaka, JapanPathology Unit, Shimane University Hospital, Izumo, Shimane, JapanFirst Department of Internal Medicine, University of the Ryukyus Hospital, Nakagami, Okinawa, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, JapanHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, JapanDivision of Innovative Medicine for Hepatobiliary & Pancreatology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, JapanDepartment of Gastroenterology and Neurology, Kagawa University Faculty of Medicine, Miki, Kagawa, JapanDepartment of Gastroenterology, Ogaki Municipal Hospital, Ogaki, JapanDepartment of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, JapanDivision of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, JapanDepartment of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, JapanDepartment of Internal Medicine, Saga Medical School, Saga University, Saga, JapanDepartment of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, JapanDepartment of Scientific Pathology Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanDivision of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, JapanHepatology Center, Saiseikai Suita Hospital, Suita, Osaka, JapanBackground and Aims: Type IV collagen 7S (COL4-7S) is a simple, noninvasive biomarker for liver fibrosis. However, whether COL4-7S can detect advanced fibrosis (AF) and predict the prognosis of metabolic dysfunction–associated steatotic liver disease (MASLD) is unclear. We examined the clinical efficacy of COL4-7S in diagnosing AF and determining MASLD prognosis. Methods: Overall, 881 Japanese patients with biopsy-proven nonalcoholic fatty liver disease between 1994 and 2020 were enrolled. Serum COL4-7S levels were measured by radioimmunoassay, and 2 cutoff points were set as 5.1 ng/mL and 7.2 ng/mL. The patients were assigned to 3 groups based on the COL4-7S level. Cox regression analysis was used to estimate the predictive performance of COL4-7S for liver-related events (LREs). Results: Overall, 866 MASLD patients were enrolled. The median follow-up period was 4.3 years. Thirty-one patients developed LREs. The area under the curve for COL4-7S in patients with AF was 0.847. The adjusted hazard ratios for LREs in 4.8 ≤ COL4-7S < 6.8 and COL4-7S ≥6.8 patients were 6.0 (P = .009) and 27.9 (P < .001) compared with COL4-7S <4.8, and the adjusted hazard ratio of AF on liver biopsy was 1.6 (P = .286). The incidence rate of LREs was low when the Fibrosis-4 Index (FIB-4) <1.30. When the FIB-4 >1.30, effective stratification of the LRE risk group was possible by stratification of COL4-7S. A combination of FIB-4 and COL4-7S stratified risk groups for future LRE development more effectively than when used singly. Conclusion: COL4-7S accurately diagnosed AF and predicted LREs. COL4-7S and a combination of FIB-4 and COL4-7S might help physicians estimate the prognosis of future LRE risk.http://www.sciencedirect.com/science/article/pii/S277257232500055XType IV Collagen 7SFibrosis-4 IndexMetabolic Dysfunction–Associated Steatotic Liver DiseaseLiver-Related Event |
| spellingShingle | Hiroshi Ishiba Yoshio Sumida Yoshihiro Kamada Hideki Fujii Michihiro Iwaki Hideki Hayashi Hidenori Toyoda Satoshi Oeda Hideyuki Hyogo Miwa Kawanaka Asahiro Morishita Kensuke Munekage Kazuhito Kawata Tsubasa Tsutsumi Koji Sawada Tatsuji Maeshiro Hiroshi Tobita Yuichi Yoshida Masafumi Naito Asuka Araki Shingo Arakaki Takumi Kawaguchi Hidenao Noritake Masafumi Ono Tsutomu Masaki Satoshi Yasuda Eiichi Tomita Masato Yoneda Akihiro Tokushige Hirokazu Takahashi Shinichiro Ueda Shinichi Aishima Atsushi Nakajima Takeshi Okanoue Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S Gastro Hep Advances Type IV Collagen 7S Fibrosis-4 Index Metabolic Dysfunction–Associated Steatotic Liver Disease Liver-Related Event |
| title | Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S |
| title_full | Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S |
| title_fullStr | Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S |
| title_full_unstemmed | Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S |
| title_short | Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S |
| title_sort | prediction of advanced fibrosis in metabolic dysfunction associated steatotic liver disease by type iv collagen 7s |
| topic | Type IV Collagen 7S Fibrosis-4 Index Metabolic Dysfunction–Associated Steatotic Liver Disease Liver-Related Event |
| url | http://www.sciencedirect.com/science/article/pii/S277257232500055X |
| work_keys_str_mv | AT hiroshiishiba predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT yoshiosumida predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT yoshihirokamada predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT hidekifujii predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT michihiroiwaki predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT hidekihayashi predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT hidenoritoyoda predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT satoshioeda predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT hideyukihyogo predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT miwakawanaka predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT asahiromorishita predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT kensukemunekage predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT kazuhitokawata predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT tsubasatsutsumi predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT kojisawada predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT tatsujimaeshiro predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT hiroshitobita predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT yuichiyoshida predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT masafuminaito predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT asukaaraki predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT shingoarakaki predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT takumikawaguchi predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT hidenaonoritake predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT masafumiono predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT tsutomumasaki predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT satoshiyasuda predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT eiichitomita predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT masatoyoneda predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT akihirotokushige predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT hirokazutakahashi predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT shinichiroueda predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT shinichiaishima predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT atsushinakajima predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s AT takeshiokanoue predictionofadvancedfibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseasebytypeivcollagen7s |